{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:38:56Z","timestamp":1783125536998,"version":"3.54.6"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:p><jats:italic>Abstract<\/jats:italic>\u2014Results of eight multicenter, randomized, placebo-controlled, double-blind, parallel-group studies were pooled to assess the efficacy of the angiotensin II\u2013receptor blocker irbesartan over the dose range of 1 to 900 mg. A total of 2955 adults with a seated diastolic blood pressure of 95 to 110 mm Hg were randomized to treatment with oral irbesartan once daily or placebo for 6 to 8 weeks. Office blood pressure was measured at trough (24\u00b13 hours after the last dose) and peak (3\u00b11 hours after the last dose) by mercury sphygmomanometry. Demographic characteristics (mean blood pressure; 151\/101 mm Hg; mean age, 54 years; 63% male; and 82% white) were similar across all dose groups. After the groups were pooled, antihypertensive efficacy was assessed by therapeutic response (trough seated diastolic blood pressure &lt;90 mm Hg or a reduction from baseline of \u226510 mm Hg) and by modeling of the maximum reductions in trough and peak seated diastolic and systolic blood pressure. Antihypertensive effects increased with increasing doses and reached a plateau at \u2265300 mg. Irbesartan 150 mg provided placebo-subtracted reductions in trough seated systolic and diastolic blood pressure of \u22488 and \u22485 mm Hg, respectively, with 56% of patients displaying a favorable response. In conclusion, irbesartan provides clinically significant blood pressure lowering, with a clear relationship between (log) dose and antihypertensive effect.<\/jats:p>","DOI":"10.1161\/01.hyp.31.6.1311","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:53:46Z","timestamp":1339462426000},"page":"1311-1316","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":73,"title":["Dose-Related Efficacy of Irbesartan for Hypertension"],"prefix":"10.1161","volume":"31","author":[{"given":"Richard A.","family":"Reeves","sequence":"first","affiliation":[{"name":"From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Sheng","family":"Lin","sequence":"additional","affiliation":[{"name":"From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kassler-Taub","sequence":"additional","affiliation":[{"name":"From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Pouleur","sequence":"additional","affiliation":[{"name":"From Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-3565(25)38210-8","volume":"265","year":"1993","unstructured":"Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B, Bernhart C, Perreaut P, Breliere J-C, Le Fur G, Nisato D. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1993;265:826\u2013834.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_2_2","first-page":"88","volume":"12","year":"1994","unstructured":"Necciari J, Denolle T, Le Coz F, Donazollo Y, Pastor G, Sissmann J. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man. J Hypertens. 1994;12:88. Abstract.","journal-title":"J Hypertens"},{"key":"e_1_3_2_3_2","first-page":"131","volume":"12","year":"1994","unstructured":"Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens. 1994;12:131. Abstract.","journal-title":"J Hypertens"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Timmermans PBMWM Smith RD. Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J. 1994;15(suppl D):79\u201387.","DOI":"10.1093\/eurheartj\/15.suppl_D.79"},{"key":"e_1_3_2_5_2","first-page":"S92","volume":"12","year":"1994","unstructured":"Sissmann J, Bouroudian M, Armagnac C, Donazollo Y, Latreille M, Panis R. Angiotensin II blockade in healthy volunteers: tolerability and impact on renin angiotensin system components of single and repeated doses of a new angiotensin II receptor antagonist SR 47436 (BMS 186295). J Hypertens. 1994;12:S92. Abstract.","journal-title":"J Hypertens"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Pool JL Guthrie RM Littlejohn TW III Raskin P Shepherd A Weber MA Weir MR Wilson TW Wright J Kassler-Taub KB Reeves RA. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens. 1998. In press.","DOI":"10.1016\/S0895-7061(97)00501-3"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-199815030-00006"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199715120-00020"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Kassler-Taub K Littlejohn T Elliott W Ruddy T Adler E. Comparative efficacy of two angiotensin II receptor antagonists irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens. 1998. In press.","DOI":"10.1016\/S0895-7061(97)00491-3"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)00150-O"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Swales JD. Meta-analysis as a guide to clinical practice. J Hypertens. 1993;11(suppl 5):S59\u2013S63.","DOI":"10.1097\/00004872-199312050-00010"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(92)90029-Y"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Simon TA Gelarden RT Freitag SA Kassler-Taub KB Davies R. The safety of irbesartan in the treatment of mild-to-moderate hypertension: results of nine randomized double-blind placebo-controlled studies. Am J Cardiol. 1998. In press.","DOI":"10.1016\/S0002-9149(98)00313-0"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Lalonde RL. Pharmacokinetic-pharmacodynamic relationships of cardiovascular drugs. In: Derendorf H Hochhaus G eds. Handbook of Pharmacokinetic\/Pharmacodynamic Correlation. Boca Raton Fla: CRC Press; 1995:197\u2013225.","DOI":"10.1201\/9780429276965-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)90944-Z"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/7.7.13S"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Kochar M Guthrie R Triscari J Kassler-Taub K Reeves RA Pulchalski J Nichola P Gelarden RT. Irbesartan in combination with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1997;10(4 pt 2):106A. Abstract.","DOI":"10.1016\/S0895-7061(97)89033-4"},{"key":"e_1_3_2_18_2","unstructured":"Weber M Saini R Kassler-Taub K Reggi D Ferdousi T Nalence A. Irbesartan combined with low-dose hydrochlorothiazide for mild-to-moderate hypertension. J Hypertens. 1998. In press. Abstract."}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.HYP.31.6.1311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T21:59:44Z","timestamp":1743371984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.HYP.31.6.1311"}},"subtitle":["An Integrated Analysis"],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1161\/01.HYP.31.6.1311"],"URL":"https:\/\/doi.org\/10.1161\/01.hyp.31.6.1311","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]},"assertion":[{"value":"1997-10-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-02-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1998-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}